Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Japan Vam & Poval Co. Ltd. manages a patent portfolio in the Biotechnology & Pharmaceuticals technology area that currently features 3 pending office actions. These actions are distributed across 3 distinct examiners, indicating a diverse range of interactions within the USPTO. One of these examiners is PARVINI, PEGAH, who is identified as the busiest examiner for the company. With 1 busiest examiner pending action, the workload is spread among the 3 distinct examiners currently handling the pending matters.
The portfolio's reach extends across 3 distinct art units, which suggests that the company's innovations in Biotechnology & Pharmaceuticals may have varied technical applications or classifications. This distribution into 3 distinct art units requires the applicant to adapt to the specific procedural nuances of 3 different administrative groups. The presence of 3 pending office actions means the company must manage multiple deadlines and responses simultaneously. Because there are 3 distinct examiners involved, the company faces a variety of examiner styles and interpretations. This structure provides a broader base of examiner interaction than a more concentrated portfolio, potentially offering different perspectives on the patentability of their inventions.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (67%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PARVINI, PEGAH | 1 | 70.2% | +12.2% |
| KIM, DANIELLE A | 1 | 37.1% | +56.3% |
| TCHERKASSKAYA, OLGA V | 1 | 55.4% | +46.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17253265 | COATING COMPOSITION, ORAL SOLID PREPARATION, AND METHOD FOR PRODUCING THE ORAL SOLID PREPARATION | TCHERKASSKAYA, OLGA V | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17793264 | POLISHING COMPOSITION | PARVINI, PEGAH | 5d overdue |
| 17292219 | BINDER | KIM, DANIELLE A | — |
| 17253265 | COATING COMPOSITION, ORAL SOLID PREPARATION, AND METHOD FOR PRODUCING THE ORAL SOLID PREPARATION | TCHERKASSKAYA, OLGA V | — |
| Art Unit | Apps |
|---|---|
| 1731 | 1 |
| 1613 | 1 |
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17793264 | POLISHING COMPOSITION | PARVINI, PEGAH | 1731 | §103 | Final Rejection | 5d overdue | Pending | Jul 15, 2022 |
| 17292219 | BINDER | KIM, DANIELLE A | 1613 | §103 | Final Rejection | — | Pending | May 07, 2021 |
| 17253265 | COATING COMPOSITION, ORAL SOLID PREPARATION, AND METHOD FOR PRODUCING THE ORAL SOLID PREPARATION | TCHERKASSKAYA, OLGA V | 1615 | §103§112 | Non-Final OA | — | Pending | Dec 17, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial